Thursday, February 25, 2021
Home Israel Medivand: Request for a clinical trial for a new product - the...

Medivand: Request for a clinical trial for a new product – the capital market

Article link

The Israeli Biotechnology Company







Page Quote News Graphs Company Profile Recommendations

More articles on the subject:

Traded on the NASDAQ and held (35%) by

Clal Biotechno

Clal Biotechno






Page Quote News Graphs Company Profile Recommendations

More articles on the subject:

Submission to the FDA for approval of a Phase I / II clinical trial of the MWPC005 product for the treatment of non-melanoma skin cancer patients. Article link

- Advertisement -

The company is preparing for the opening of the trial in the United States in the second quarter of this year, while a Phase II “investigative-researcher” study will be conducted at Soroka Medical Center.

It is a dermatological biologic drug that is in the development stages and is based on the active ingredient of the two drugs it has already developed from Devand: NexoBrid for the treatment of burns and EscharEx for the treatment of chronic wounds and healing wounds. According to Medivand, a preclinical study combining existing scientific evidence with models of skin cancer suggests that the product may help treat low-risk, non-melanoma malignant skin tumors.

“Non-melanoma skin cancers, including basal cell carcinoma, are the most common of all cancers, and in this respect there is significant market potential,” he said. Sharon Malka, CEO of Divand. “We believe MWPC005 has the potential to be an effective, non-invasive treatment for basal cell carcinoma, with no side effects associated with currently existing skin care treatments or their long duration of treatment.”

Basal cell carcinoma (BCC) is a non-melanoma skin cancer that develops in the basal layers of the epidermis. According to the American Cancer Society, this is the most diagnosed skin cancer in the United States, with about 4.3 million diagnosed each year.

Comments on the article(0):

Your response has been received and will be published subject to system policies.

For a new response

Your response was not sent due to a communication problem, please try again.

Return to comment

Important Alert

Dear reader.
I hope you are in health and well.
I offer you important instructions regarding this article

  • We only want readers to access information quickly and easily using other multilingual content, rather than information only available in a specific language.
  • We always respect the copyright of the author's content and always include
    the original link of the Source Article , and if the author does not agree, leave the report below the article, the article will be edited or deleted at the author's request. Thank you so much! Warm greetings!


Source link


Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

Recent Comments